Dual inhibition of EGFR and mTOR pathways in small cell lung cancer

BACKGROUND: In this report we investigated the combination of epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway inhibition as a possible new therapeutic strategy for small cell lung cancer (SCLC). METHODS: EGFR, p-AKT, p-ERK, p-mTOR and p-p70s6K protein express...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, K, Bago-Horvath, Z, Berger, W, Haitel, A, Cejka, D, Werzowa, J, Filipits, M, Herberger, B, Hayden, H, Sieghart, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938245/
https://www.ncbi.nlm.nih.gov/pubmed/20683448
http://dx.doi.org/10.1038/sj.bjc.6605761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2938245/
https://www.ncbi.nlm.nih.gov/pubmed/20683448
http://dx.doi.org/10.1038/sj.bjc.6605761

Ejemplares similares